1. Home
  2. KG vs BDSX Comparison

KG vs BDSX Comparison

Compare KG & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KG

Kestrel Group Ltd.

HOLD

Current Price

$10.90

Market Cap

118.0M

Sector

Finance

ML Signal

HOLD

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$14.95

Market Cap

122.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KG
BDSX
Founded
N/A
2005
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Precision Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
118.0M
122.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
KG
BDSX
Price
$10.90
$14.95
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
20.3K
132.2K
Earning Date
03-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$88,499,000.00
Revenue This Year
N/A
$25.26
Revenue Next Year
N/A
$19.70
P/E Ratio
$1.38
N/A
Revenue Growth
N/A
24.08
52 Week Low
$8.07
$0.25
52 Week High
$35.37
$20.21

Technical Indicators

Market Signals
Indicator
KG
BDSX
Relative Strength Index (RSI) 44.55 50.67
Support Level $9.90 $6.33
Resistance Level $12.75 $20.21
Average True Range (ATR) 0.96 1.70
MACD -0.25 -0.54
Stochastic Oscillator 29.91 14.62

Price Performance

Historical Comparison
KG
BDSX

About KG Kestrel Group Ltd.

Kestrel Group Ltd is specializes in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers. The Group facilitates insurance transactions utilizing its management contracts with four insurance carriers. Its line business includes casualty, workers' compensation, catastrophe-exposed property, and non-catastrophe-exposed property, with diverse risk durations, sizes, and product types.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Share on Social Networks: